Sarepta Therapeutics,, Inc. Common Stock
$20.11
-$0.56 (-2.71%)
$19.62Day Range$20.74
Key Statistics
Market Cap
$2.12B
Shares Outstanding
105.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 4, 1997
Round Lot
100
Locale
US
Trading Data
Day Open
$20.63
Day High
$20.74
Day Low
$19.62
Volume
6.29M
VWAP
$20.07
Prev Close
$20.67
Transactions
--
Acc. Volume
--
About Sarepta Therapeutics,, Inc. Common Stock
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
PHARMACEUTICAL PREPARATIONSSIC 2834835 employees215 FIRST STREET, CAMBRIDGE, MA, 02142617-274-4000IPO Jun 4, 1997US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000873303
- Composite FIGI
- BBG000BCJ161
- Share Class FIGI
- BBG001S6KJC6
- Ticker Root
- SRPT
- SIC Code
- 2834
About Sarepta Therapeutics,, Inc. Common Stock (SRPT) Stock
Sarepta Therapeutics,, Inc. Common Stock (SRPT) closed the 2026-09-18 session at $20.11, down 2.71% versus the previous close (-0.56). The stock opened at $20.63 and traded between $19.62 and $20.74 during that session. Session trading volume was 6.3M shares. The volume-weighted average price (VWAP) is $20.07.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Sarepta Therapeutics,, Inc. Common Stock has a market capitalization of $2.12 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. SRPT is listed on the XNAS exchange. The company employs approximately 835 people. Sarepta Therapeutics,, Inc. Common Stock is headquartered in CAMBRIDGE, MA. The recorded listing date is 1997-06-04.
On this page you can find market SRPT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.